Enhanced growth inhibition by combination differentiation therapy with ligands of peroxisome proliferator-activated receptor-γ and inhibitors of histone deacetylase in adenocarcinoma of the lung

Clinical Cancer Research

Volumn 8, Issue 4, 2002, Pages 1206-1212

  Chang, Tsg Hui ^a   Szabo, Eva ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CELL MARKER; CYCLIN D1; GELSOLIN; HISTONE DEACETYLASE INHIBITOR; LIGAND; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA LIGAND; PROTEIN MAD1; PROTEIN P21; SODIUM PHENYLBUTYRATE; TRICHOSTATIN A; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CELL DIFFERENTIATION; CELL LINEAGE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENCY; GROWTH INHIBITION; HUMAN; HUMAN CELL; LUNG ADENOCARCINOMA; LUNG ALVEOLUS CELL TYPE 2; LUNG NON SMALL CELL CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ADENOCARCINOMA; BASIC HELIX-LOOP-HELIX LEUCINE ZIPPER TRANSCRIPTION FACTORS; BLOTTING, WESTERN; CARCINOMA, NON-SMALL-CELL LUNG; CELL DIFFERENTIATION; CELL DIVISION; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLINS; DNA-BINDING PROTEINS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SYNERGISM; GELSOLIN; GENE EXPRESSION REGULATION, NEOPLASTIC; HISTONE DEACETYLASES; HUMANS; HYDROXAMIC ACIDS; LIGANDS; LUNG NEOPLASMS; PHENYLBUTYRATES; RECEPTORS, CYTOPLASMIC AND NUCLEAR; REPRESSOR PROTEINS; RNA; THIAZOLES; THIAZOLIDINEDIONES; TRANSCRIPTION FACTORS; TUMOR CELLS, CULTURED;

EID: 0036554932     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Spiegelman, B. M. PPAR-γ. Adipogenic regulator and thiazolidinedione receptor. Diabetes, 47: 507-514, 1998.
2. Tontonoz, P., Singer, S., Forman, B. M., Sarraf, P., Fletcher, J. A., Fletcher, C. D. M., Brun, R. P., Mueller, E., Altiok, S., Oppenheim, H., Evans, R. M., and Spiegelman, B. M. Terminal differentiation of human liposarcoma cells induced by ligands for peroxisome proliferator-activated receptorγ and the retinoid X receptor. Proc. Natl. Acad. Sci. USA, 94: 237-241, 1997.
3. Mueller, E., Sarraf, P., Tontonoz, P., Evans, R. M., Martin, K. J., Zhang, M., Fletcher, C., Singer, S., and Spiegelman, B. M. Terminal differentiation of human breast cancer through PPAR-γ. Mol. Cell, 1: 465-470, 1998.
4. Sarraf, P., Mueller, E., Jones, D., King, F. J., DeAngelo, D. J., Partridge, J. B., Holden, S. A., Chen, L. B., Singer, S., Fletcher, C., and Spiegelman, B. M. Differentiation and reversal of malignant changes in colon cancer through PPARγ. Nat. Med., 4: 1046-1052, 1998.
5. Chang, T-H., and Szabo, E. Induction of differentiation and apoptosis by ligands of peroxisome proliferator-activated receptor γ in non-small cell lung cancer. Cancer Res., 60: 1129-1138, 2000.
6. Marks, P. A., Richon, V. M., and Rifkind, R. A. Histone deacetylase inhibitors: inducers of differentiation or apoptosis of transformed cells. J. Natl. Cancer Inst., 92: 1210-1216, 2000.
7. Timmermann, S., Lehrmann, H., Polesskaya, A., and Harel-Bellan, A. Histone acetylation and disease. Cell. Mol. Life Sci., 58: 728-736, 2001.
8. Hebbes, T. R., Thorne, A. W., and Crane-Robinson, C. A direct link between core histone acetylation and transcriptionally active chromatin. EMBO J., 7: 1395-1403, 1988.
9. Struhl, K. Histone acetylation and transcriptional regulatory mechanisms. Genes Dev., 12: 599-606, 1998.
10. Kuo, M. K., Zhou, J., Jambeck, P., Churchill, M. E., and Allis, C. D. Histone acetyltransferase activity of yeast Gcn5p is required for the activation of target genes in vivo. Genes Dev., 12: 627-639, 1998.
11. Kuo, M. H., and Allis, C. D. Roles of histone acetyltransferases and deacetylases in gene regulation. Bioessays, 20: 615-626, 1998.
12. Ogryzko, V. V., Schilitz, R. L., Russanova, V., Howard, B. H., and Nakatani. Y. The transcriptional coactivators p300 and CBP are histone acetyltransferases. Cell, 87: 953-959, 1996.
13. Puri, P. L. Sartorelli, V., Yang, X. J., Hamamori, Y., Ogryzko, V. V., Howard, B. H., Kedes, L., Wang, J. Y., Graessmann, A., Nakatani, Y., and Levrero, M. Differential roles of p300 and PCAF acetyltransferases in muscle differentiation. Mol. Cell, 1: 35-45, 1997.
14. Muraoka, M., Konishi, M., Kikuchi-Yanoshita, R., Tanakta, K., Shitara, N., Chong, J. M., Iwama, T., and Miyaki, M. p300 gene alterations in colorectal and gastric carcinomas. Oncogene, 12: 1565-1569, 1996.
15. Lin, R. J., Nagy, L., Inoue, S., Shao, W., Miller, W. H., Jr., and Evans, R. M. Role of the histone deacetylase complex in acute promyelocytic leukaemia. Nature (Lond.), 391: 811-814, 1998.
16. Piscitelli, S. C., Thibault, A., Figg, W. D., Tompkins, A., Headlee, D., Lieberman, R., Samid, D., and Myers, C. E. Disposition of phenylbutyrate and its metabolites, phenylacetate and phenylacetylglutamine. J. Clin. Pharm., 35: 368-373, 1995.
17. Dosaka-Akita, H., Hommura, F., Fujita, H., Kinoshita, I., Nishi, M., Morikawa, T., Katoh, H., Kawakami, Y., and Kuzumaki, N. Frequent loss of gelsolin expression in non-small cell lung cancers of heavy smokers. Cancer Res., 58: 322-327, 1998.
18. Tanaka, M., Mullauer, L., Ogiso, Y., Fumita, H., Moriya, S., Furuuchi, K., Harabayashi, T., Shinohara, N., Koyanagi, T., and Kizimaki, N. Gelsolin. A candidate for suppressor of human bladder cancer. Cancer Res., 55: 3228-3232, 1995.
19. Cultraro, C. M., Bino, T., and Segal, S. Function of the c-Myc antagonist Mad1 during a molecular switch from proliferation to differentiation. Mol. Cell. Biol., 17: 2353-2359, 1997.
20. Jarrard, J. A., Linnoila, R. I., Lee, H. R., Steinberg, S. M., Witschi, H., and Szabo, E. MUC1 is a novel marker for the type II pneumocyte lineage during lung carcinogenesis. Cancer Res., 58: 5582-5589, 1998.
21. Demetri, G. D., Fletcher, C. D. M., Mueller, E., Sarraf, P., Naujoks, R., Campbell, N., Spiegelman, B. M., and Singer, S. Induction of solid tumor differentiation by the peroxisome proliferator-activated receptor-γ ligand troglitazone in patients with liposarcoma. Proc. Natl. Acad. Sci. USA, 96: 3951-3956, 1999.
22. Vigushin, D. M., Ali, S., Pace, P. E., Mirsaidi, N., Ito, K., Adcock, I., and Coombes, R. C. Trichostatin A is a histone deacetylase inhibitor with potent antitumor activity against breast cancer in vivo. Clin. Cancer Res., 7: 971-976, 2001.
23. Betticher, D. C., Heighway, J., Hasleton, P. S., Altermatt, J. H., Ryder, W. D. J., Cerny, T., and Thatcher, N. Prognostic significance of CCNDI (cyclin D1) overexpression in primary resected non-small cell lung cancer. Br. J. Cancer, 73: 294-300, 1996.
24. Lonardo, F., Rusch, V., Langenfeld, J., Dmitrovsky, E., and Klimstra, D. S. Overexpression of cyclins D1 and E is frequent in bronchial preneoplasia and precedes squamous cell carcinoma development. Cancer Res., 59: 2470-2476, 1999.
25. Yu, Q., Geng, Y., and Sicinski, P. Specific protection against breast cancers by cyclin D1 ablation. Nature (Lond.), 411: 1017-1021, 2001.
26. cip1/WAFI in differentiation of primary mouse keratinocytes independent of cell cycle control. Science (Wash. DC), 280: 1069-1072, 1998.
27. Wang, J., and Walsh, K. Resistance to apoptosis conferred by cdk inhibitors during myocyte differentiation. Science (Wash. DC), 273: 359-361, 1996.
28. Warrell, R. P., He, L-Z., Richon, V., Calleja, E., and Pandolfi, P. P. Therapeutic targeting of transcription in acute promyelocytic leukemia by use of an inhibitor of histone deacetylase. J. Natl. Cancer Inst., 90: 1621-1625, 1998.